Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2023-04-07 Legal Proceedings Report
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(mRNA 기반 코로나-19 예방백신 (EG-COVID) 호주 부스터 임상 제 1/2a상 시험 계획 변경 승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a material management decision ('투자판단 관련 주요경영사항'). It details the approval of a clinical trial amendment for a COVID-19 vaccine. Since this is a formal regulatory disclosure of a material event that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2023-04-07 Korean
투자판단관련주요경영사항(mRNA 기반 코로나-19 예방백신 (EG-COVID) 국내 임상 제 1/2a상 시험 조기 종료)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Eutilex/Eyegene) submitted to the KRX (Korea Exchange). It details the early termination of a clinical trial (EG-COVID) and provides specific reasons for this decision, such as changes in market conditions and strategic shifts in development. This type of disclosure regarding material business events, specifically clinical trial status updates, falls under the category of general regulatory announcements for material management matters.
2023-04-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including the purpose of holding (influence on management) and specific transaction details. This falls under the 'Major Shareholding Notification' category.
2023-04-06 Korean
투자판단관련주요경영사항(아이진 mRNA 기반 코로나-19 예방백신 (EG-COVID) 호주 부스터 임상 제 1/2a상 시험 계획 변경 승인 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details a clinical trial amendment application for a COVID-19 vaccine. Since it is a formal regulatory disclosure regarding business operations and clinical trial status, and does not fit into specific categories like financial reports or shareholder meetings, it is classified as a general regulatory filing.
2023-03-29 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides the official outcomes of the shareholder votes held on 2023-03-23, including the approval of financial statements, director/auditor compensation limits, and stock option grants. This falls directly under the definition of a Declaration of Voting Results.
2023-03-23 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the fiscal year 2022 (Jan 1, 2022 to Dec 31, 2022) for EyeGene Inc. It contains detailed company information, history, capital changes, and business descriptions, which are standard components of an Annual Report (10-K equivalent in the Korean market). It is a comprehensive financial and operational disclosure document, not a mere announcement or certification. FY 2022
2023-03-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.